Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
0.8001
+0.0552 (7.41%)
At close: Jan 7, 2026, 4:00 PM EST
0.7999
-0.0002 (-0.02%)
Pre-market: Jan 8, 2026, 7:43 AM EST
Tenaya Therapeutics Employees
Tenaya Therapeutics had 97 employees as of December 31, 2024. The number of employees decreased by 43 or -30.71% compared to the previous year.
Employees
97
Change (1Y)
-43
Growth (1Y)
-30.71%
Revenue / Employee
n/a
Profits / Employee
-$971,732
Market Cap
133.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 97 | -43 | -30.71% |
| Dec 31, 2023 | 140 | -1 | -0.71% |
| Dec 31, 2022 | 141 | 35 | 33.02% |
| Dec 31, 2021 | 106 | 31 | 41.33% |
| Dec 31, 2020 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TNYA News
- 26 days ago - Tenaya Stock Plunges After $60 Million Equity Offering - Benzinga
- 27 days ago - Tenaya Therapeutics Announces Pricing of Public Offering - GlobeNewsWire
- 27 days ago - Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript - Seeking Alpha
- 27 days ago - Tenaya Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 27 days ago - Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC - GlobeNewsWire
- 27 days ago - Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy - GlobeNewsWire
- 2 months ago - Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript - Seeking Alpha
- 2 months ago - Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewsWire